Combined effects of radiation and interleukin-13 receptor-targeted cytotoxin on glioblastoma cell lines

International Journal of Radiation Oncology Biology Physics

Volumn 63, Issue 1, 2005, Pages 230-237

  Kawakami, Koji ^a   Kawakami, Mariko ^a   Liu, Qi ^a   Puri, Raj K ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Cytotoxin; Glioblastoma; Interleukin 13 receptor; Radiation

Indexed keywords

BIOASSAY; BIOMEDICAL ENGINEERING; CELLS; CYTOLOGY; DISEASE CONTROL; PATIENT MONITORING; REACTION KINETICS; RNA; TOXICITY;

BINDING ASSAYS; CYTOTOXIN; GLIOBLASTOMA; INTERLEUKIN-13 RECEPTOR;

RADIOTHERAPY;

ANTINEOPLASTIC AGENT; CHIMERIC PROTEIN; CYTOTOXIN; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR; MESSENGER RNA; PSEUDOMONAS EXOTOXIN; BACTERIAL TOXIN; EXOTOXIN; HYBRID PROTEIN; IL13RA1 PROTEIN, HUMAN; IMMUNOTOXIN; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER INHIBITION; CELL SURVIVAL; CELL VIABILITY; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERMETHOD COMPARISON; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RADIATION DOSE; RECEPTOR BINDING; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CELL CULTURE; DRUG EFFECT; DRUG SCREENING; METABOLISM; METHODOLOGY; MULTIMODALITY CANCER THERAPY; RADIATION EXPOSURE; UPREGULATION;

BACTERIAL TOXINS; COMBINED MODALITY THERAPY; EXOTOXINS; GLIOBLASTOMA; HUMANS; IMMUNOTOXINS; INTERLEUKIN-13 RECEPTOR ALPHA1 SUBUNIT; RADIATION DOSAGE; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-13; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY; UP-REGULATION;

EID: 26944496119     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.05.017     Document Type: Article

References (32)

1. Reiter Y. Recombinant immunotoxins in targeted cancer cell therapy. Adv Cancer Res 2001;81:93-124.
2. Frankel AE, Kreitman RJ, Sausville EA. Targeted toxins. Clin Cancer Res 2000;6:326-334.
3. Puri RK. Introduction to special issue: Targeted toxins for glioma therapy. J Neuro-Oncol 2003;65:1-2.
4. Kawakami M, Kawakami K, Takahashi S, et al. Analysis of interleukin-13 receptor α2 expression in human pediatric brain tumors. Cancer 2004;101:1036-1042.
5. Kawakami M, Leland P, Kawakami K, et al. Mutation and functional analysis of IL-13 receptors in human malignant glioma cells. Oncol Res 2001;12:459-467.
6. Joshi BH, Plautz GE, Puri RK. IL-13 receptor α chain: A novel tumor associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res 2000;60: 1168-1172.
7. Liu H, Jacobs BS, Liu J, et al. Interleukin-13 sensitivity and receptor phenotypes of human glial cell lines: Non-neoplastic glia and low-grade astrocytoma differ from malignant glioma. Cancer Immunol Immunother 2000;49:319-324.
8. Caput D, Laurent P, Kaghad M, et al. Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor α chain. J Biol Chem 1996;271:16921-16926.
9. Donaldson DD, Whitters MJ, Fitz LJ, et al. The murine IL-13 receptor α2: Molecular cloning, characterization, and comparison with murine IL-13 receptor α1. J Immunol 1998;161: 2317-2324.
10. Kawakami K, Taguchi J, Murata T, et al. The interleukin-13 receptor α2 chain: An essential component for binding and internalization but not for IL-13 induced signal transduction through STAT6 pathway. Blood 2001;97:2673-2679.
11. Bernard J, Treton D, Vermot-Desroches C, et al. Expression of interleukin 13 receptor in glioma and renal cell carcinoma: IL13Rα2 as a decoy receptor for IL13. Lab Invest 2001;81: 1223-1231.
12. Rahaman SO, Sharma P, Harbor PC, et al. IL-13Rα2, a decoy receptor for IL-13 act as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells. Cancer Res 2002;62:1103-1109.
13. Debinski W, Obiri NI, Pastan I, et al. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J Biol Chem 1995; 270:16775-16780.
14. Kioi M, Kawakami K, Puri RK. Analysis of antitumor activity of an IL-13 receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin. Clin Cancer Res 2004; 10:6231-6238.
15. Husain SR, Joshi BH, Puri RK. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int J Cancer 2001;92:168-175.
16. Kawakami M, Kawakami K, Puri RK. Intratumoral administration of interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death in human malignant glioma tumor xenografts. Mol Cancer Ther 2002;1:999-1007.
17. Kawakami K, Puri RK. Interleukin-13 and cancer. In: Brombacher F, editor. Interleukin-13. Austin, Texas: Landes Bioscience; 2003. p. 65-78
18. Ram Z, Barnett G, Vogelbaum M, et al. Pre-operative infusion of IL13-PE38QQR cytotoxin by convection-enhanced delivery (CED) in recurrent malignant glioma: A phase I/II study [Abstract]. American Society of Clinical Oncology annual meeting, 2003.
19. Weingart J, Strauss LC, Grossman SA, et al. Phase I/II study: Intratumoral infusion of IL13-PE38QQR cytotoxin for recurrent supratentorial malignant glioma [Abstract]. Neuro-Oncol 2002;4:379.
20. Lang F, Kunwar S, Strauss L, et al. A clinical study of convection-enhanced delivery of IL13-PE38QQR cytotoxin pre- and post-resection of recurrent GBM (Abstr.). 70th annual meeting of the American Association of Neurological Surgeons (AANS), Chicago, IL, April 6-11, 2002.
21. Prados MD, Levin V. Biology and treatment of malignant glioma. Semin Oncol 2000;27:1-10.
22. Prados MD, Seiferheld W, Sandler HM, et al. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: Final report of RTOG 9404. Int J Radiat Oncol Biol Phys 2004;58:1147-1152.
23. Lammering G, Valerie K, Lin PS, Hewit TH, et al. Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance. Radiother Oncol 2004;72:267-273.
24. Kim K-U, Xiao J, Ni H-T, et al. Changes in expression of transferring, insulin-like growth factor 1, and interleukin 4 receptors after irradiation of cells of primary malignant brain tumor cell lines. Radiat Res 2003;160:224-231.
25. Puri RK, Leland P, Obiri NI, et al. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood 1996; 87:4333-4339.
26. Kawakami K, Kawakami M, Leland P, et al. Internalization property of interleukin-4 receptor α chain increases cytotoxic effect of IL-4 receptor targeted cytotoxin in cancer cells. Clin Cancer Res 2002;8:258-266.
27. Yuyama N, Davies DE, Akaiwa M, et al. Analysis of novel disease-related genes in bronchial asthma. Cytokine 2002;19: 287-296.
28. Gueven N, Keating KE, Chen P, et al. Epidermal growth factor sensitizes cells to ionizing radiation by down-regulating protein mutated in ataxia-telangiectasia. J Biol Chem 2001; 276:8884-8891.
29. HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2. Clin Cancer Res 2000;6:3334-3341.
30. Wei B-R, Ghetie M-A, Vitetta ES. The combined use of an immunotoxin and a radioimmunoconjugate to treat disseminated human B-cell lymphoma in immunodeficient mice. Clin Cancer Res 2002;6:631-642.
31. Bobo RH, Laske DW, Akbasak A, et al. Convection-enhanced delivery to macromolecules in the brain. Proc Natl Acad Sci USA 1994;91:2076-2080.
32. Kawakami K, Kawakami M, Kioi M, et al. Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model. J Neurosurg 2004;101: 1004-1011.